Patients with Elevated Baseline Liver Enzymes Do Not Have Higher Frequency of Hepatotoxicity from Lovastatin than Those with Normal Baseline Liver Enzymes

No abstract is available for this paper.

• Publication year

  2005

• Venue

  American Journal of the Medical Sciences

• Publication date

  2005-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/00000441-200502000-00002PMID 15711421
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Patients with elevated liver enzymes are not at higher risk for statin hepatotoxicity.

  2004cited by this paper
• Systemic Levels of Lipid Peroxidation and Its Metabolic and Dietary Correlates in Patients with Nonalcoholic Steatohepatitis

  2004cited by this paper
• Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox.

  2004cited by this paper
• Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

  2003cited by this paper
• The Safety of HMG-CoA Reductase Inhibitors in Special Populations at High Cardiovascular Risk

  2003cited by this paper
• Hepatotoxicity of hypolipidemic drugs.

  2003cited by this paper
• Safety and statin therapy: reconsidering the risks and benefits.

  2003cited by this paper
• A qualitative study of barriers to the use of statins and the implementation of coronary heart disease prevention in primary care.

  2003cited by this paper
• Safety considerations for statins

  2002cited by this paper
• Hepatotoxicity of Commonly Used Drugs: Nonsteroidal Anti-Inflammatory Drugs, Antihypertensives, Antidiabetic Agents, Anticonvulsants, Lipid-Lowering Agents, Psychotropic Drugs

  2002cited by this paper
• Update on nonalcoholic fatty liver disease.

  2002cited by this paper
• An examination of the effect of cytochrome P450 drug interactions of hydroxymethylglutaryl-coenzyme A reductase inhibitors on health care utilization: a Canadian population-based study.

  2002cited by this paper
• Low prevalence of lipid lowering drug use in older men with established coronary heart disease

  2002cited by this paper
• Use of Lipid-Lowering Medications at Discharge in Patients With Acute Myocardial Infarction: Data From the National Registry of Myocardial Infarction 3

  2001cited by this paper
• Lipid lowering medication and hepatotoxicity

  2001cited by this paper
• Statins: underused by those who would benefit

  2000cited by this paper
• Fatty Infiltration of Liver in Hyperlipidemic Patients

  2000cited by this paper
• Acute cholestatic hepatitis associated with pravastatin

  1999cited by this paper
• Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity.

  1999cited by this paper
• Atorvastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin.

  1999cited by this paper
• The Regenstrief Medical Record System: a quarter century experience

  1999cited by this paper
• Acute hepatitis induced by HMG-CoA reductase inhibitor, lovastatin

  1994cited by this paper
• Lovastatin-induced hepatitis.

  1992cited by this paper
• Liver side effects associated with simvastatin therapy

  1991cited by this paper
• Drug induced liver disease.

  1983cited by this paper
• Hepatotoxicity: The adverse effects of drugs and other chemicals on the liver

  1978cited by this paper

• Drug‐Induced Liver Injury in Patients With Chronic Liver Disease

  2025cites this paper
• Efficacy and safety of statins for nonalcoholic/metabolic dysfunction-associated fatty liver diseases: a systematic review and meta-analysis

  2025cites this paper
• Successful Treatment of Drug-induced Acute Liver Failure with Therapeutic Plasma Exchange: A Case Report

  2024cites this paper
• ACG Clinical Guideline: Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury.

  2021cites this paper
• EURASIAN ASSOCIATION OF CARDIOLOGY (EAC)/ RUSSIAN NATIONAL ATHEROSCLEROSIS SOCIETY (RNAS, RUSSIA) GUIDELINES FOR THE DIAGNOSIS AND CORRECTION OF DYSLIPIDEMIA FOR THE PREVENTION AND TREATMENT OF ATHEROSCLEROSIS (2020)

  2020cites this paper
• Drug-Induced Liver Injury in the Setting of Chronic Liver Disease.

  2020cites this paper
• Drug-induced liver steatosis in patients with HIV infection.

  2019cites this paper
• A prospective study of hepatic safety of statins used in very elderly patients

  2019cites this paper
• 2019 Taiwan Society of Lipids and Atherosclerosis expert consensus statement on statin intolerance.

  2019cites this paper
• 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

  2019cites this paper
• TYPE II DIABETES MELLITUS ; FREQUENCY OF ASYMPTOMATIC ELEVATION OF LIVER FUNCTION ENZYMES IN TYPE II DIABETES MELLITUS PATIENTS USING STATINS

  2019cites this paper
• Metabolic Comorbidities and Risk of Development and Severity of Drug-Induced Liver Injury

  2019cites this paper
• Statin Safety and Associated Adverse Events: A Scientific Statement From the American Heart Association

  2019cites this paper
• 2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk.

  2019cites this paper
• Consensus: guidelines: best practices for detection, assessment and management of suspected acute drug‐induced liver injury during clinical trials in patients with nonalcoholic steatohepatitis

  2019cites this paper
• MUSCLE ADVERSE EVENTS AMONG USERS OF SIMVASTATIN IN PRIMARY HEALTH CARE: COLLABORATIVE DRUG THERAPY MANAGEMENT

  2018cites this paper
• Natural products berberine and curcumin exhibited better ameliorative effects on rats with non-alcohol fatty liver disease than lovastatin.

  2018cites this paper
• Effects of Statins on the Hepatic Decompensation, Mortality, Complications and Drug Safety in Liver Cirrhosis: A Systematic Review and Meta-Analysis

  2018cites this paper
• Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis.

  2018cites this paper
• Guía ESC/EAS 2016 sobre el tratamiento de las dislipemias

  2017cites this paper
• Liver Safety of Statins in Prediabetes or T2DM and Nonalcoholic Steatohepatitis: Post Hoc Analysis of a Randomized Trial

  2017cites this paper
• Addition of simvastatin to carvedilol non responders: A new pharmacological therapy for treatment of portal hypertension

  2017cites this paper
• Non-alcoholic Fatty Liver Disease in Obesity

  2016cites this paper
• Statins and its hepatic effects: Newer data, implications, and changing recommendations

  2016cites this paper
• Statins and the Liver.

  2016cites this paper
• The pharmacotherapy of cirrhosis: concerns and proposed investigations and solutions

  2016cites this paper
• Statins for All Patients with Hypertension—It is still not Prime Time!

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias: The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European Atherosclerosis Society (EAS) Developed with the special contribution of the European Assocciation for Cardiovascular Prevention

  2016cites this paper
• 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias.

  2016cites this paper
• Diagnosis and Management of Drug-Induced Liver Injury (DILI) in Patients with Pre-Existing Liver Disease

  2016cites this paper
• Current and future directions in the treatment and prevention of drug-induced liver injury: a systematic review

  2016cites this paper
• Statin-induced liver injury in an area endemic for hepatitis B virus infection: risk factors and outcome analysis.

  2016cites this paper
• Non-Alcoholic Fatty Liver Disease (NAFLD): The Lipid Disease of the Liver and the Effect of Statins

  2015cites this paper
• The Art and Science of Diagnosing and Managing Drug-induced Liver Injury in 2015 and Beyond.

  2015cites this paper
• Nonalcoholic fatty liver disease: evidence based management

  2015cites this paper
• Statins and the liver.

  2015cites this paper
• Severe hepatic injury associated with different statins in patients with chronic liver disease: A nationwide population‐based cohort study

  2015cites this paper
• Nonalcoholic fatty liver disease and statins.

  2015influential citation
• Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.

  2015cites this paper
• Drug-Induced Liver Injury.

  2015cites this paper
• Best Practice & Research Clinical Endocrinology & Metabolism

  2014cites this paper
• Is it Simvastatin harmful in children? A case report

  2014cites this paper
• Drug-Induced Liver Injury - Tantangan dalam Diagnosis

  2014cites this paper
• Effects of statins on the risk of hepatocellular carcinoma.

  2014cites this paper
• Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study

  2014cites this paper
• Non‐alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies

  2014cites this paper
• ACG Clinical Guideline: The Diagnosis and Management of Idiosyncratic Drug-Induced Liver Injury

  2014cites this paper
• Review article: management of chronic hepatitis C in patients with contraindications to anti‐viral therapy

  2014cites this paper
• Lipid lowering in liver and chronic kidney disease.

  2014cites this paper
• Statins alter the hepatobiliary transport of unconjugated and conjugated bilirubin in sandwich-cultured rat hepatocytes.

  2014cites this paper
• Statins and Hepatitis C Virus Infection: An Old Therapy With New Scope

  2014cites this paper
• Resistant Nonalcoholic Fatty Liver Disease Amelioration With Rosuvastatin and Pioglitazone Combination Therapy in a Patient With Metabolic Syndrome

  2014cites this paper
• Pathogenesis and therapeutic approaches for non-alcoholic fatty liver disease.

  2014cites this paper
• Prescribing a Statin to a Cirrhotic Patient to Reduce Hepatic Decompensation and Improve Survival: Impossible You Say?

  2014cites this paper
• Management of nonalcoholic fatty liver disease: an evidence-based clinical practice review.

  2014cites this paper
• Monitoring of Lipids, Enzymes, and Creatine Kinase in Patients on Lipid-Lowering Drug Therapy

  2013cites this paper
• Non-alcoholic Fatty Liver Disease: Pharmacotherapy

  2013cites this paper
• Clinical manifestations and management of drug-induced liver diseases

  2013cites this paper
• Hepatotoxicity of Cardiovascular and Antidiabetic Drugs

  2013cites this paper
• Benefits & risks of statin therapy for primary prevention of cardiovascular disease in Asian Indians – A population with the highest risk of premature coronary artery disease & diabetes

  2013cites this paper
• Statins in Nonalcoholic Fatty Liver Disease and Steatohepatitis: Updated Review

  2013cites this paper
• Review article: prescribing medications in patients with cirrhosis – a practical guide

  2013cites this paper
• Risk Factors for Drug-Induced Liver Disease

  2013cites this paper
• Nonalcoholic Fatty Liver Disease in Adults: The Impact of Diet and Other Therapeutic Interventions on Clinical and Histological Outcomes

  2013cites this paper
• Corrigendum:The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cites this paper
• Clinical Perspective: Statins and the Liver—Harmful or Helpful?

  2012cites this paper
• Non-alcoholic fatty liver disease: An important consideration in patients with CVD

  2012cites this paper
• Dyslipidemia in Patients with Nonalcoholic Fatty Liver Disease

  2012cites this paper
• Multidisciplinary Pharmacotherapeutic Options for Nonalcoholic Fatty Liver Disease

  2012cites this paper
• The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease

  2012cites this paper
• The challenge of managing dyslipidemia in patients with nonalcoholic fatty liver disease

  2012cites this paper
• Factores de riesgo y mecanismos de toxicidad hepática. Daño hepático inducido por medicamentos y tóxicos (excluido el alcohol)

  2012cites this paper
• Statin treatment in patients with elevated liver enzymes: pitch to proceed.

  2012cites this paper
• The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology.

  2012cites this paper
• The Diagnosis and Management of Non-alcoholic Fatty Liver Disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

  2012cites this paper
• Effects of interventions on intra- and interobserver agreement on interpretation of nonalcoholic fatty liver disease histology.

  2011cites this paper
• Hepatotoxicity in 2011--advancing resolutely.

  2011cites this paper
• Considerations for safe use of statins: liver enzyme abnormalities and muscle toxicity.

  2011cites this paper
• Extended Release Niacin-Laropiprant in Patients with Hypercholesterolemia or Mixed Dyslipidemias Improves Clinical Parameters

  2011cites this paper
• Lipid Targets During Statin Treatment in Dyslipidemic Patients Affected by Nonalcoholic Fatty Liver Disease

  2011cites this paper
• Idiosyncratic Drug-Induced Liver Injury: A Clinical Update

  2011cites this paper
• ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

  2011cites this paper
• Drug‐Induced Liver Injury

  2011cites this paper
• Non-alcoholic steatohepatitis: An update in pathophysiology, diagnosis and therapy

  2011cites this paper
• Portal hypertension: pathophysiology, diagnosis, and treatment.

  2011cites this paper
• Optimal statin type and dosage for vascular patients.

  2011cites this paper
• Statins in the treatment of dyslipidemia in the presence of elevated liver aminotransferase levels: a therapeutic dilemma.

  2010cites this paper
• Hepatotoxicity Fears Contribute to Underutilization of Statin Medications by Primary Care Physicians

  2010cites this paper
• Hepatic endothelial dysfunction and abnormal angiogenesis: new targets in the treatment of portal hypertension.

  2010cites this paper
• Statins in Portal Hypertension

  2010cites this paper
• Standardization of nomenclature and causality assessment in drug‐induced liver injury: Summary of a clinical research workshop

  2010cites this paper
• Drug-induced liver injury: what was new in 2008?

  2009cites this paper
• Prescribing statins to patients with nonalcoholic fatty liver disease: real cardiovascular benefits outweigh theoretical hepatotoxic risk.

  2009cites this paper
• [Statins: hepatotoxicity and monitoring].

  2009cites this paper
• Epidemiology of idiosyncratic drug-induced liver injury.

  2009cites this paper
• Liver Safety in Patients with Type 2 Diabetes Treated with Pioglitazone

  2009cites this paper
• Acute hepatitis caused by a natural lipid-lowering product: when "alternative" medicine is no "alternative" at all.

  2009cites this paper
• Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial.

  2009cites this paper
• The effect of pioglitazone on the liver of streptozotocin-induced diabetic albino Wistar rats.

  2009cites this paper
• Use of statins in patients with liver disease

  2009cites this paper